Pronota, Molecuence Partner on Stroke Biomarker Deal

Feb 22, 2011

NEW YORK (GenomeWeb News) – German biomarker firm Pronota today announced a deal with Molecuence for the discovery and validation of stroke biomarkers.

Pronota will use its MASStermind protein biomarker platform for the discovery stage of the deal, and its MASSterclass technology for the verification work.

Financial and other terms of the deal were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Of Mice and Microbes

Mice in New York harbor both antibiotic-resistant bacteria and novel viruses, according to a new analysis of their fecal microbiomes.

Guidelines for Genomics in Africa

Human Heredity and Health in Africa Initiative has issued guidelines for genomic research in the region, according to Nature News.

So Many Choices

The Associated Press reports that an ethicist predicts that prenatal diagnosis and other advances will lead to more choices being available to prospective parents.